Jianmin Group released its 2026 half-year report. First-half net profit attributable to the parent fell 19.7% year on year to 177 million yuan. Operating revenue was 1.61 billion yuan, down 10.7% year on year. Net profit attributable to the parent excluding non-recurring items was 153 million yuan, down 21.5% year on year. Net operating cash flow was 120 million yuan, up 116.3% year on year. Second-quarter operating revenue was 738 million yuan, down 19.1% year on year, and net profit attributable to the parent was 89.48 million yuan, down 19.0% year on year. The company said there was no material change in its main business. Pharmaceutical industry revenue and pharmaceutical distribution revenue fell 9.24% and 13.31% respectively.
Jianmin Pharmaceutical Group Co LtdNet profit attributable to parent fell 19.7% to 177 million yuan, with revenue down 10.7%.
